Julian Schulze Zur Wiesch
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Plasmodium falciparum | 4 | 2020 | 337 | 1.94 | Why? |
| Malaria, Falciparum | 3 | 2020 | 377 | 1.76 | Why? |
| 5'-Nucleotidase | 2 | 2020 | 21 | 1.55 | Why? |
| Apyrase | 2 | 2020 | 39 | 1.02 | Why? |
| Lymphocyte Activation | 5 | 2020 | 2742 | 0.96 | Why? |
| Antigens, CD | 4 | 2020 | 984 | 0.95 | Why? |
| Hepatitis Delta Virus | 2 | 2019 | 54 | 0.94 | Why? |
| Hepatitis D | 2 | 2019 | 48 | 0.93 | Why? |
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 98 | 0.80 | Why? |
| Epitopes, T-Lymphocyte | 3 | 2019 | 2262 | 0.76 | Why? |
| Antigens, Protozoan | 1 | 2019 | 121 | 0.75 | Why? |
| Raltegravir Potassium | 1 | 2019 | 132 | 0.74 | Why? |
| Natural Killer T-Cells | 1 | 2020 | 191 | 0.73 | Why? |
| Malaria Vaccines | 1 | 2019 | 90 | 0.72 | Why? |
| Sofosbuvir | 3 | 2017 | 518 | 0.72 | Why? |
| Quinolones | 1 | 2019 | 167 | 0.69 | Why? |
| HIV Integrase Inhibitors | 1 | 2019 | 173 | 0.69 | Why? |
| Plasma Cells | 1 | 2020 | 464 | 0.68 | Why? |
| CD8-Positive T-Lymphocytes | 5 | 2020 | 5837 | 0.64 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 275 | 0.63 | Why? |
| Hepacivirus | 5 | 2018 | 1509 | 0.63 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.62 | Why? |
| Histocompatibility Antigens Class II | 1 | 2019 | 383 | 0.61 | Why? |
| Killer Cells, Natural | 3 | 2020 | 2093 | 0.59 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2020 | 760 | 0.55 | Why? |
| Receptors, IgG | 1 | 2018 | 578 | 0.54 | Why? |
| Immunologic Memory | 4 | 2021 | 3362 | 0.54 | Why? |
| Lymph Nodes | 2 | 2018 | 1060 | 0.54 | Why? |
| Hepatitis C, Chronic | 3 | 2017 | 973 | 0.52 | Why? |
| HIV Infections | 6 | 2019 | 11620 | 0.52 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.47 | Why? |
| Hepatitis B, Chronic | 1 | 2019 | 616 | 0.46 | Why? |
| T-Lymphocyte Subsets | 2 | 2018 | 1387 | 0.43 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2017 | 698 | 0.43 | Why? |
| Hepatitis E virus | 3 | 2019 | 306 | 0.43 | Why? |
| Viremia | 2 | 2017 | 1020 | 0.41 | Why? |
| Hepatitis E | 3 | 2019 | 319 | 0.41 | Why? |
| GPI-Linked Proteins | 3 | 2020 | 317 | 0.38 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2020 | 4545 | 0.37 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.35 | Why? |
| B-Lymphocytes | 3 | 2020 | 4418 | 0.32 | Why? |
| Fluorenes | 2 | 2016 | 101 | 0.30 | Why? |
| Programmed Cell Death 1 Receptor | 3 | 2020 | 724 | 0.29 | Why? |
| HIV-1 | 2 | 2017 | 3365 | 0.29 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.27 | Why? |
| Benzimidazoles | 2 | 2016 | 275 | 0.26 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.25 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.20 | Why? |
| Perforin | 1 | 2020 | 136 | 0.20 | Why? |
| Receptors, KIR2DL3 | 1 | 2018 | 2 | 0.20 | Why? |
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2018 | 6 | 0.20 | Why? |
| Receptors, KIR2DL2 | 1 | 2018 | 4 | 0.20 | Why? |
| Receptors, KIR3DS1 | 1 | 2018 | 2 | 0.19 | Why? |
| Hepatitis delta Antigens | 1 | 2018 | 6 | 0.19 | Why? |
| Malaria, Cerebral | 1 | 2018 | 37 | 0.19 | Why? |
| IMP Dehydrogenase | 1 | 2017 | 13 | 0.18 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 290 | 0.18 | Why? |
| Oxazines | 1 | 2019 | 279 | 0.17 | Why? |
| Receptors, Complement 3d | 1 | 2017 | 60 | 0.17 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2017 | 58 | 0.17 | Why? |
| Hepatitis C | 3 | 2018 | 1514 | 0.17 | Why? |
| Leptospirosis | 1 | 2018 | 103 | 0.17 | Why? |
| Aged | 16 | 2021 | 215776 | 0.17 | Why? |
| Germany | 7 | 2021 | 9196 | 0.17 | Why? |
| HLA-B Antigens | 1 | 2018 | 166 | 0.17 | Why? |
| HLA-C Antigens | 1 | 2018 | 195 | 0.17 | Why? |
| Ki-67 Antigen | 1 | 2017 | 139 | 0.16 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.16 | Why? |
| Antiviral Agents | 7 | 2019 | 41703 | 0.16 | Why? |
| Adult | 20 | 2021 | 244371 | 0.16 | Why? |
| Cells, Cultured | 4 | 2020 | 5835 | 0.16 | Why? |
| Piperazines | 1 | 2019 | 445 | 0.16 | Why? |
| Adenosine | 1 | 2020 | 509 | 0.16 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.15 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.15 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.15 | Why? |
| Transfusion Reaction | 1 | 2018 | 245 | 0.15 | Why? |
| Th17 Cells | 1 | 2021 | 657 | 0.15 | Why? |
| Neuromyelitis Optica | 1 | 2020 | 397 | 0.14 | Why? |
| Female | 22 | 2021 | 380317 | 0.14 | Why? |
| Receptors, Immunologic | 1 | 2018 | 555 | 0.14 | Why? |
| Infertility, Male | 1 | 2019 | 322 | 0.14 | Why? |
| Male | 19 | 2021 | 367725 | 0.14 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.13 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 529 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 952 | 0.13 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.13 | Why? |
| Histocompatibility Antigens Class I | 1 | 2018 | 624 | 0.13 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.12 | Why? |
| Cell Proliferation | 2 | 2018 | 1973 | 0.12 | Why? |
| Flow Cytometry | 2 | 2018 | 2393 | 0.12 | Why? |
| Rituximab | 1 | 2020 | 1096 | 0.12 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.11 | Why? |
| Humans | 33 | 2021 | 930598 | 0.11 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Leukocytes, Mononuclear | 2 | 2018 | 2115 | 0.11 | Why? |
| Anti-Retroviral Agents | 1 | 2019 | 1099 | 0.11 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.10 | Why? |
| DNA, Viral | 2 | 2019 | 2521 | 0.10 | Why? |
| Interferon-gamma | 1 | 2020 | 2711 | 0.10 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.10 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.10 | Why? |
| Viral Load | 3 | 2019 | 15850 | 0.09 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Cytokines | 3 | 2019 | 15010 | 0.09 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.08 | Why? |
| Interferons | 1 | 2019 | 2885 | 0.08 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.08 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Interferon Type I | 1 | 2019 | 2789 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.07 | Why? |
| Immunocompromised Host | 2 | 2019 | 5150 | 0.07 | Why? |
| Blood Donors | 1 | 2018 | 2956 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.07 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Antibodies, Viral | 3 | 2020 | 51949 | 0.06 | Why? |
| Signal Transduction | 1 | 2020 | 7207 | 0.06 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Liver | 1 | 2018 | 4007 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.06 | Why? |
| Ribavirin | 2 | 2019 | 1182 | 0.06 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.06 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.05 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.05 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Clone Cells | 1 | 2021 | 312 | 0.05 | Why? |
| DNA, Circular | 1 | 2019 | 26 | 0.05 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.05 | Why? |
| Plasmodium berghei | 1 | 2018 | 27 | 0.05 | Why? |
| Multiprotein Complexes | 1 | 2018 | 182 | 0.04 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.04 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Receptors, CXCR5 | 1 | 2017 | 35 | 0.04 | Why? |
| Tropical Climate | 1 | 2018 | 179 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.04 | Why? |
| Mutagenesis | 1 | 2019 | 394 | 0.04 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.04 | Why? |
| Sequence Homology | 1 | 2018 | 448 | 0.04 | Why? |
| Receptors, CXCR3 | 1 | 2017 | 159 | 0.04 | Why? |
| Treatment Outcome | 3 | 2017 | 51732 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2017 | 393 | 0.04 | Why? |
| Coinfection | 1 | 2016 | 6820 | 0.04 | Why? |
| Hepatocytes | 1 | 2019 | 549 | 0.04 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.04 | Why? |
| Proline | 1 | 2017 | 345 | 0.04 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.04 | Why? |
| Disease Resistance | 1 | 2017 | 236 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2021 | 843 | 0.03 | Why? |
| Oligopeptides | 1 | 2017 | 576 | 0.03 | Why? |
| In Vitro Techniques | 1 | 2017 | 1027 | 0.03 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.03 | Why? |
| Interferon-beta | 1 | 2019 | 979 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| AIDS Vaccines | 1 | 2017 | 452 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.03 | Why? |
| Interferon-alpha | 1 | 2019 | 1442 | 0.03 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
| Universities | 1 | 2021 | 4374 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Travel | 1 | 2018 | 7220 | 0.01 | Why? |
| Vaccines | 1 | 2018 | 3692 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |